IP Verse

Tablets Comprising Glp-1 Agonist And Enteric Coating

Patent No. EP3250191 (titled "Tablets Comprising Glp-1 Agonist And Enteric Coating") was filed by Novo Nordisk on Jan 28, 2016. The application was issued on Jan 17, 2024.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HEXALOct 17, 2024MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3250191

NOVO NORDISK
Application Number
EP16701684A
Filing Date
Jan 28, 2016
Status
Granted And Under Opposition
Dec 15, 2023
Publication Date
Jan 17, 2024
External Links
Slate, Register , Google Patents